Compared with ibrutinib, zanubrutinib appears to have more of a benefit for patients with regards to less atrial fibrillation, hypertension, and other cardiac effects, explained Constantine S. Tam, ...

Constantine S. Tam, MBBS, MD, consulting hematologist and associate professor, Peter MacCallum Cancer Centre, explains findings of his abstract at EHA2022 showing the impact of Australia’s ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Zanubrutinib ...

Current prognostic tools in myelofibrosis (MF) fail to identify patients at the highest risk of death and are limited by their applicability only to the time of diagnosis. We aimed to define an ...

"The oral regimen of ibrutinib alone followed by combined ibrutinib and venetoclax delivered a promising rate of disease clearance in previously untreated patients with CLL, with 75 percent and 72 ...

(Nanowerk News) Scientists from RMIT University and the Doherty Institute have developed a new blood test that could screen cancer patients to help make their treatment safer and more effective. The ...

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve ...

Researchers found that, despite being heavily immunocompromised, hematology patients generate strong cellular immune responses against SARS-CoV-2 after vaccination, on par with that of healthy ...

Scientists from RMIT University and the Doherty Institute have developed a new blood test that could screen cancer patients to help make their treatment safer and more effective. About one in two ...

Professor Stephen Kent (left) with Dr Yi (David) Ju next to the flow cytometer in a Doherty Institute lab where they analysed blood samples. Scientists from RMIT University and the Doherty Institute ...